Updating results

984 results

Sort: Relevance | Date

Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]

In development [GID-TA10399] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492

In development [GID-TA10441] Expected publication date: TBC

Technology appraisal guidance In development

Andexanet alfa for reversing anticoagulation [ID1101]

In development [GID-TA10440] Expected publication date: 10 June 2020

Technology appraisal guidance In development

Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer ID1495

In development [GID-TA10395] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

In development [GID-TA10484] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for treating relapsed or refractory classical Hodgkin's lymphoma after 1 or more multi-agent chemotherapy regimens [ID1557]

In development [GID-TA10485] Expected publication date: 03 February 2021

Technology appraisal guidance In development

Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

In development [GID-TA10486] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

In development [GID-TA10449] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

In development [GID-TA10465] Expected publication date: TBC

Technology appraisal guidance In development

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for treating interstitial lung disease caused by systemic sclerosis (ID1420)

In development [GID-TA10427] Expected publication date: TBC

Technology appraisal guidance In development

Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]

In development [GID-TA10504] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]

In development [GID-TA10510] Expected publication date: TBC

Technology appraisal guidance In development

Acalabrutinib for treating chronic lymphocytic leukaemia ID1613

In development [GID-TA10532] Expected publication date: TBC

Technology appraisal guidance In development

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

In development [GID-TA10429] Expected publication date: TBC

Technology appraisal guidance In development

Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

In development [GID-TA10539] Expected publication date: TBC

Technology appraisal guidance In development

Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

In development [GID-TA10523] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

In development [GID-TA10483] Expected publication date: TBC

Technology appraisal guidance In development

Dupilumab for treating severe asthma

In development [GID-TA10276] Expected publication date: 06 May 2020

Technology appraisal guidance In development

Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Technology appraisal guidance In development

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma [ID1576]

In development [GID-TA10463] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416) [ID1577]

In development [GID-TA10475] Expected publication date: 22 April 2020

Technology appraisal guidance In development

Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Technology appraisal guidance In development

ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

In development [GID-TA10448] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

In development [GID-TA10447] Expected publication date: TBC

Technology appraisal guidance In development

Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 08 July 2020

Technology appraisal guidance In development

Nivolumab in combination for untreated advanced gastric cancer [ID1465]

In development [GID-TA10352] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: TBC

Technology appraisal guidance In development

Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

In development [GID-TA10251] Expected publication date: TBC

Technology appraisal guidance In development

Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

In development [GID-TA10249] Expected publication date: TBC

Technology appraisal guidance In development

Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

In development [GID-TA10248] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated endometrial cancer [ID1205]

In development [GID-TA10243] Expected publication date: TBC

Technology appraisal guidance In development

ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed chronic lymphocytic leukaemia [ID1083]

In development [GID-TA10260] Expected publication date: TBC

Technology appraisal guidance In development

Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

In development [GID-TA10252] Expected publication date: TBC

Technology appraisal guidance In development

Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Technology appraisal guidance In development

Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

In development [GID-TA10361] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Technology appraisal guidance In development

Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352

In development [GID-TA10319] Expected publication date: TBC

Technology appraisal guidance In development

Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336

In development [GID-TA10316] Expected publication date: TBC

Technology appraisal guidance In development

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 August 2020

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]

In development [GID-TA10531] Expected publication date: TBC

Technology appraisal guidance In development

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development